12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Inovio preclinical data

In a mouse model of limb ischemia, Inovio's hypoxia-inducible factor 1 alpha ( HIF1A; HIF1-alpha) plasmid DNA therapy delivered using the company's Cellectra...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >